Laura Schwenk

Dr. Laura Schwenk


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LSLaura Schwenk
Laura Schwenk
OROliver Rohland
Oliver Rohland
ADAladdin Ali Deeb
Aladdin Ali Deeb
FDFelix Dondorf
Felix Dondorf
USUtz Settmacher
Utz Settmacher
FRFalk Rauchfuss
Falk Rauchfuss
Background: Data about liver transplantation for mixed tumors from hepatocellular carcinoma to cholangiocarcinoma are limited. Furthermore, the diagnosis of intrahepatic cholangiocarcinoma or combined tumors in a cirrhotic liver is considered a contraindication for transplantation. Our aim was to evaluate the long-term outcomes of patients with incidental cholangiocarcinoma or combined tumors after liver transplantation. Methods: In our descriptive analysis, data were evaluated from all patients since 2010 who received a liver transplant due to an assumed hepatocellular carcinoma at Jena University Hospital. Survival rates were determined using the Kaplan–Meier method. Results: Between January 2010 and December 2022, an incidental intrahepatic cholangiocarcinoma was found in eight patients post-transplant. Four combined hepatocellular and cholangiocarcinoma and four sole intrahepatic cholangiocarcinomas were found. A recurrence through distant metastases from combined hepatocellular- and cholangiocarcinoma was found in one patient at one year after transplantation. Another patient developed a pulmonary primary tumor independently one year post-transplant. The recurrence rate was at 14.3%. While two patients died, the 1- and 5-year overall survival rates post-transplant were 87.5% and 75%, respectively. Conclusion: Patients with intrahepatic cholangiocarcinoma or combined hepatocellular- and cholangiocarcinoma could profit from liver transplantation.

25 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
OROliver Rohland
Oliver Rohland
LFLea Freye
Lea Freye
LSLaura Schwenk
Laura Schwenk
ADAladdin Ali Deeb
Aladdin Ali Deeb
MAMichael Ardelt
Michael Ardelt
FDFelix Dondorf
Felix Dondorf
Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.

17 October 2023 in Die Chirurgie
Verified
Journal Article
Closed access
PDF file
LSLaura Schwenk
Laura Schwenk
FRFalk Rauchfuß
Falk Rauchfuß
AAAladdin Ali-Deeb
Aladdin Ali-Deeb
FDFelix Dondorf
Felix Dondorf
OROliver Rohland
Oliver Rohland
USUtz Settmacher
Utz Settmacher

21 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LSLaura Schwenk
Laura Schwenk
FDFelix Dondorf
Felix Dondorf
OROliver Rohland
Oliver Rohland
ADAladdin Ali Deeb
Aladdin Ali Deeb
USUtz Settmacher
Utz Settmacher
FRFalk Rauchfuss
Falk Rauchfuss
Background: The use of neoadjuvant therapies in patients with hepatocellular carcinoma prior to liver transplantation has gained increasing popularity in recent years. To date, there are only limited data investigating the impact of neoadjuvant therapy on post-transplant survival. Methods: In this retrospective study, we evaluated patients with hepatocellular carcinoma who underwent deceased donor or living donor liver transplantation at Jena University Hospital between 2019 and 2023. Comprehensive clinical and pathological variables were systematically analyzed, including correlations between neoadjuvant therapy use, tumor burden and overall survival. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 107 patients were included in the analysis, of whom 90 received neoadjuvant therapy prior to transplantation. Treatment modalities comprised SIRT, TACE, liver resection and combined SIRT and TACE. The 1-, 3-, and 5-year OS rates following transplantation were 93.5%, 82.2%, and 79.4%, respectively. Recurrence-free survival at 1, 3, and 5 years was 91.6%, 85.0%, and 83.2%, respectively. Among the various neoadjuvant strategies, SIRT and TACE yielded the highest OS rates. Patients listed outside the transplantation criteria (Milan, UCSF, up-to-seven) at the time of initial diagnosis who underwent SIRT had significantly better OS than those outside the criteria who underwent TACE. In contrast, among patients within the Milan, UCSF and up-to-seven criteria, TACE was associated with superior OS compared with SIRT. Conclusion: The use of neoadjuvant therapies confers a significant survival benefit following liver transplantation in patients with HCC. TACE appears to be most suitable for patients listed within established transplantation criteria, who consequently have a lower tumor burden. In contrast, SIRT is more beneficial for patients with a higher tumor burden and those beyond standard transplantation criteria. A limitation of our study, however, is that the included SIRT cohort comprised only 24 patients, and TACE was preferentially performed in patients with a lower tumor burden, which means that a selection bias cannot be fully excluded. Overall, further studies are required to define the optimal bridging strategies.


22 April 2026 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Open access
PDF file
OROliver Rohland
Oliver Rohland
FDFelix Dondorf
Felix Dondorf
LSLaura Schwenk
Laura Schwenk
AAAladdin Ali-Deeb
Aladdin Ali-Deeb
MAMichael Ardelt
Michael Ardelt
FRFalk Rauchfuß
Falk Rauchfuß
Living donor liver transplantation (LDLT) represents an important alternative to deceased donor transplantation, particularly in times of organ shortage. This study analyzes the selection process of living liver donors at a German transplant center that performs both living and deceased donor liver transplantations. In a retrospective analysis, potential living liver donors were evaluated. Medical data and reasons for donor exclusion were collected, and recipient cohorts were categorized according to transplantation indication and urgency. Donor outcomes were also assessed. Between January 2013 and December 2023, a total of 594 potential living donors were evaluated at Jena University Hospital. Of these, 124 successfully proceeded to donation. During the outpatient evaluation phase, 357 donors were excluded. Subsequently, 237 individuals underwent inpatient assessments, of whom an additional 100 were excluded. The main reasons for donor exclusion were medical or psychological contraindications (n = 160), as well as donor-independent factors such as disease progression in the recipient (n = 90) or withdrawal of consent by either the recipient or the donor (n = 54). Particularly among recipients with malignant diseases who had little or no chance of receiving a deceased donor organ, a high willingness to donate was observed—even among distant relatives or unrelated donors. A standardized evaluation protocol improves the efficiency of living donor liver transplantation within the Eurotransplant region and ensures donor safety. Diverse contraindications necessitate targeted exclusion diagnostics for individual potential donors.